文献速递肿瘤 PET/CT放射性药物与辐射防护

18F-PSMA-11用于前列腺癌PET显像的辐射剂量学与生物分布

Radiation Dosimetry and Biodistribution of 18F-PSMA-11 for PET Imaging of Prostate Cancer.
PubMed 文献 · J Nucl Med · 2019-04-26

本研究纳入6例既往治疗后疑似前列腺癌复发患者,按2 MBq/kg给予18F-PSMA-11后行多时间点低剂量PET/CT显像,评估给药安全性与辐射剂量学。结果显示该药可安全给药,未观察到药物相关不良事件,平均有效剂量为12.8 ± 0.6 μSv/MBq,总辐射剂量低于其他PSMA PET显像剂,与18F-DCFPyL处于同一范围。

要点

  • 18F-PSMA-11可安全给药,6例中未观察到药物相关不良事件。
  • 平均有效剂量为12.8 ± 0.6 μSv/MBq,低于其他PSMA PET显像剂。
  • 注药后5 h经尿液排泄29.0% ± 5.9%,血浆游离18F比例随时间升高。

核心结论

  • 18F-PSMA-11可安全给药,平均有效剂量为12.8 ± 0.6 μSv/MBq。
  • 其总辐射剂量低于其他PSMA PET显像剂,与18F-DCFPyL处于同一范围。

研究设计与样本

  • 研究纳入6例既往治疗后疑似前列腺癌复发的患者,年龄62-68岁(均值66 ± 2岁)。
  • 按2 MBq/kg体重给予18F-PSMA-11,于注药后0、20、50、90、300 min行低剂量PET/CT显像。
  • 监测生命体征评估给药安全,检测全血计数与生化指标评估毒性。
  • 依据国际放射防护委员会最新建议,使用IDAC-Dose 2.1进行辐射剂量学分析。
  • 于注药后不同时间点采集静脉血样,并在20、50、90 min测定血浆游离18F比例以评估脱氟率。

主要发现

  • 注药后18F-PSMA-11自血液中快速清除。
  • 注药后5 h,29.0% ± 5.9%的放射性经尿液排泄。
  • 血浆游离18F比例由注药后20 min的9.7% ± 1.0%升至90 min的22.2% ± 1.5%。
  • 示踪剂摄取最高的器官为肾脏、膀胱、脾脏和肝脏。
  • 未观察到研究药物相关不良事件。

关键数值与推荐

  • 按2 MBq/kg体重给药,平均有效剂量为12.8 ± 0.6 μSv/MBq。
  • 注药后5 h尿液排泄比例为29.0% ± 5.9%。
  • 血浆游离18F比例20 min为9.7% ± 1.0%,90 min为22.2% ± 1.5%。

临床怎么用

  • 18F-PSMA-11可按2 MBq/kg体重给药用于前列腺癌PET显像,并需关注其辐射剂量学特征。
  • 因其平均有效剂量较低,可作为PSMA PET显像的备选显像剂之一。

局限性

  • 研究样本量仅6例,结果的外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prostate-specific membrane antigen (PSMA) is highly overexpressed in prostate cancer. Many PSMA analog radiotracers for PET/CT prostate cancer staging have been developed, such as 68Ga-PSMA-11. This radiotracer has achieved good results in multiple clinical trials, but because of the superior imaging characteristics of 18F-fluoride, 18F-PSMA-11 was developed. The aim of this study was to evaluate the administration safety and radiation dosimetry of 18F-PSMA-11. Methods: Six patients (aged 62-68 y; mean, 66 ± 2 y) with suspected prostate cancer recurrence after previous treatment were administered 2 MBq of 18F-PSMA-11 per kilogram of body weight and then underwent low-dose PET/CT imaging at 0, 20, 50, 90, and 300 min after injection. To evaluate the safety of administration, vital parameters were monitored. To assess toxicity, full blood count and biochemical parameters were determined. According to the latest International Commission on Radiological Protection recommendations, radiation dosimetry analysis was performed using IDAC-Dose 2.1. For blood activity measurement, small samples of venous blood were collected at various time points after injection. The unbound 18F-fluoride fraction was determined in plasma at 20, 50, and 90 min after administration to evaluate the defluorination rate of 18F-PSMA-11. Results: After injection, 18F-PSMA-11 cleared rapidly from the blood. At 5 h after injection, 29.0% ± 5.9% of the activity was excreted in urine. The free 18F fraction in plasma increased from 9.7% ± 1.0% 20 min after injection to 22.2% ± 1.5% 90 min after injection. The highest tracer uptake was observed in kidneys, bladder, spleen, and liver. No study drug-related adverse events were observed. The calculated mean effective dose was 12.8 ± 0.6 μSv/MBq. Conclusion:18F-PSMA-11 can be safely administered and results in a mean effective dose of 12.8 ± 0.6 μSv/MBq. Therefore, the total radiation dose is lower than for other PSMA PET agents and in the same range as 18F-DCFPyL.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Piron S, De Man K, Van Laeken N, et al. Radiation Dosimetry and Biodistribution of 18F-PSMA-11 for PET Imaging of Prostate Cancer. J Nucl Med. 2019. PMID: 31028165. doi:10.2967/jnumed.118.225250

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。